Loading news...
Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to provide runway into 2031 FOSTER CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that management will provide an update on 2026 priorities and program milestones during the Company's presentation at the 44th Annual J.P.
FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended.
Amy Burroughs, Terns Pharmaceuticals CEO, joins 'Fast Money' to talk its latest cancer drug data
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are $747.5 million. All of the securities were offered by Terns.
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering price of $40.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be $650 million, excluding any exercise of the underwriters' option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,437,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 11, 2025, subject to customary closing conditions. All of the securities are being offered by Terns.
Terns Pharmaceuticals, Inc. stock has surged 770% YTD, driven by strong TERN-701 data in chronic myeloid leukemia, or CML, the latest outstanding data set shared yesterday. TERN-701 demonstrated superior major molecular response rates versus Novartis' Scemblix, with robust safety and efficacy in heavily pre-treated CML patients. Management is prioritizing TERN-701, raising $400M for pivotal studies, with Phase 3 initiation and regulatory milestones as key upcoming catalysts.
FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Terns expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares and pre-funded warrants to be sold in the offering will be offered by Terns. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript
64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses > 320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage oncology company, today announced that updated and expanded data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in patients with previously treated chronic myeloid leukemia (CML) are being presented today at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025 in Orlando, FL.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report)'s share price reached a new 52-week high on Saturday. The stock traded as high as $30.25 and last traded at $29.36, with a volume of 6237699 shares trading hands. The stock had previously closed at $27.13. Analysts Set New Price Targets TERN has been the subject
New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable assets under management (AUM).
Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) traded up 9.6% during mid-day trading on Friday after Mizuho raised their price target on the stock from $32.00 to $33.00. Mizuho currently has an outperform rating on the stock. Terns Pharmaceuticals traded as high as $22.81 and last traded at $22.71. 981,061 shares were traded during
FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be presenting at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30 p.m.
Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash, cash equivalents and marketable securities of $295 million, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today reported financial results for the third quarter ended September 30, 2025, and provided corporate updates.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) shares gapped up before the market opened on Tuesday after HC Wainwright upgraded the stock from a neutral rating to a buy rating. The stock had previously closed at $14.03, but opened at $15.50. HC Wainwright now has a $20.00 price target on the stock. Terns Pharmaceuticals
FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns.
Terns Pharmaceuticals Inc. (NASDAQ:TERN) stock is trading higher on Monday, with a session volume of 24.36 million, compared to its average volume of 1.31 million, according to Benzinga Pro.
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8 th at 4:30pm ET FOSTER CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in participants with previously treated chronic myeloid leukemia (CML) has been selected for oral presentation on December 8, 2025 at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, FL.
On Tuesday, Terns Pharmaceuticals Inc. (NASDAQ:TERN) shared topline 12-week results from its FALCON Phase 2 trial of TERN-601.